Sunday 18 October 2026
Export PALI’s income statement to Excel — free account
Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.41
0.13
−8.44%
Follow PALI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
3.23 | — | — | — |
+8 more quarters Free account |
P/S ratio |
585.15 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(58.11) | — | — | — | |
P/B ratio |
3.63 | — | — | — | |
Price to Tangible BV |
3.63 | — | — | — | |
EV/Sales |
419.99 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(17.43) | — | — | — | |
EV/FCF |
(17.42) | — | — | — | |
Quick Ratio |
23.96 | 23.60 | 28.77 | 1.50 | |
Current Ratio |
24.26 | 23.71 | 28.95 | 1.96 | |
Net Debt/EBITDA |
10.70 | 12.34 | 13.33 | 1.72 | |
Debt/Assets |
0.00% | 0.00% | 0.29% | 3.03% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.07 | |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.72 | 0.41 | 0.35 | 1.24 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Interest Coverage |
— | (10,748.00) | (4,990.50) | (584.40) | |
Research and Development Expense of Revenue |
1,480.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
959.60% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
957.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.28 | — | — | — | |
Graham Number |
2.90 | — | — | — | |
Earnings Yield |
30.99% | — | — | — | |
Free Cash Flow Yield |
(4.12%) | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.02) | (0.06) | (0.48) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.02) | (0.06) | (0.48) | |
Cash per Share |
0.59 | 0.63 | 2.40 | 0.70 | |
Shareholders Equity per Share |
0.58 | 0.61 | 2.32 | 0.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.58 | 0.61 | 2.32 | 0.43 | |
Free Cash Flow |
(7.60) | (3.89) | (3.14) | (3.55) | |
Working Capital |
122.01 | 127.62 | 129.59 | 3.35 | |
Net Current Asset Value |
121.69 | 127.29 | 129.26 | 3.07 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.00 | — | — | — | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
0.97 | — | — | — | |
Average Payables |
1.60 | 1.72 | 0.94 | 0.90 | |
Average Assets |
66.99 | 70.75 | 72.61 | 8.15 | |
Average Common Equity |
62.18 | 66.34 | 68.43 | 4.91 |
Columns are period end dates